Product
OncoSil System for Healthcare Professionals

OncoSil Medical is an interventional oncology medical device company making a single-use brachytherapy device.
oncosil.comCrawled Nov 18, 2026
OncoSil System for Healthcare Professionals
OncoSil Medical develops medical devices for interventional oncology, using Phosphorous 32 microparticles to target tumors in cancer patients.
Pancreatic cancer is a type of cancer that begins in the pancreas, an organ located behind the stomach. The pancreas plays a crucial role in digestion by producing enzymes that help break down food, as well as hormones, including insulin, that regulate blood sugar levels.
The UK Private Programme is intended for patients who have:
OncoSil reports a matched-cohort study showing that adding its device to chemotherapy improves survival, local disease control, and resection rates in patients with unresectable locally advanced pancreatic cancer.
Chief Executive Officer and Managing Director
OncoSil Medical maintains a continuous disclosure policy, updating shareholders via ASX announcements, its website, newsletters, and annual reports.
The **TRIPP-FFX trial** demonstrates **local disease control and safety** using **Phosphorus-32 (P-32) microparticles combined with FOLFIRINOX** in patients with locally advanced pancreatic adenocarcinoma. Early results confirm the treatment regimen achieves its primary efficacy and tolerability goals. Researchers evaluate this combination as a potential new therapeutic approach for unresectable pancreatic tumors.
OncoSil Medical presents updated **TRIPP-FFX** clinical study results, including a new Per Protocol (PP) analysis, at **ESMO GI 2026**. The findings highlight safety and promising clinical outcomes for its localized treatment targeting **unresectable locally advanced pancreatic cancer (LAPC)**. The study was delivered as a **Rapid Oral Presentation**, underscoring its significance in the medical oncology field.
OncoSil Medical obtains Australian TGA approval for its OncoSil device, enabling its use in treating locally advanced pancreatic cancer (LAPC) in combination with gemcitabine-based chemotherapy. The device targets a critical unmet need in pancreatic cancer care by integrating with standard chemotherapy regimens. The approval follows regulatory review of clinical data supporting its safety and efficacy in this patient population.
OncoSil Medical secures TGA approval for its OncoSil™ device, expanding its use for treating unresectable locally advanced pancreatic cancer (LAPC) alongside gemcitabine-based chemotherapy. The device targets localized treatment options in this patient group. The approval enables broader availability in Australia under the company’s existing focus on pancreatic cancer therapies.
OncoSil Medical presents interim results from its OSPREY Registry at ESGE Days 2026, showing promising safety and efficacy for its OncoSil™ device in treating patients with unresectable locally advanced pancreatic cancer (LAPC). The data reflects real-world clinical practice outcomes, demonstrating early potential for the localized treatment approach. The company specializes in medical devices targeting this challenging cancer type.